摘要
目的探究多西紫杉醇联合洛铂在晚期卵巢癌的新辅助化疗的临床效果和安全性。方法选择九江市第一人民医院妇科60例经腹腔镜证实为IIIc期的卵巢上皮性癌患者,随机分为研究组(n=30)和对照组(n=30),对照组给予多西紫杉醇联合顺铂治疗,研究组给予多西紫杉醇联合洛铂治疗,3周1疗程。治疗3个疗程后进行疗效和毒副作用的对比。结果研究组与对照组相比,进展期患者比例少,差异有统计学意义(P<0.05);治疗有效率(70.00%)和疾控控制率(93.33%)明显高于对照组,差异均具有统计学意义(P<0.05);研究组急性和亚急性不良反应情况和毒性分类级别均优于对照组,差异具有统计学差异(P<0.05)。结论多西紫杉醇联合洛铂治疗晚期卵巢癌的治疗效果明确、急性和亚急性不良反应情况少且毒性分类级别低,患者容易耐受,值得临床推广。
Objective To investigate the clinical effect and safety of docetaxel combined with loplatin in neoadjuvant chemotherapy for advanced ovarian cancer.Methods 60 cases of ovarian epithelial cancer patients in the department of gynaecology of NO.1 people's hospital of Jiujiang were selected and randomly divided into study group(n=30)and control group(n=30).The control group received docetaxel combined with cisplatin,and the study group received docetaxel combined with loplatin,for a course of 3 weeks.After 3 courses of treatment,the efficacy and side effects were compared.Results Compared with the control group,the proportion of patients in the advanced stage was less,and the difference was statistically significant(P<0.05).The effective rate(70.00%)and the disease control rate(93.33%)were significantly higher than the control group,with statistically significant differences(P<0.05).Acute and subacute adverse reactions and toxicity levels in the study group were better than those in the control group,with statistically significant differences(P<0.05).Conclusion The efficacy of docetaxel combined with loplatin in the treatment of advanced ovarian cancer is clear,acute and subacute adverse reactions are few and the toxicity classification is low,patients are easy to tolerate,and it is worthy of clinical promotion.
作者
洪进德
张蓉蓉
郭卉
彭晓华
洪琴
Hong Jinde;Zhang Rongrong;Guo Hui;Peng Xiaohua;Hong Qin(Department of gynaecology,Jiujiang NO.1 People's Hospital,Jiujiang,332000,China)
出处
《当代医学》
2019年第36期4-6,共3页
Contemporary Medicine
基金
江西省卫生计生委科技计划(20172289)
关键词
多西紫杉醇
洛铂
新辅助化疗
临床效果
安全性
Docetaxel
Los platinum
Neoadjuvant chemotherapy
Clinical effect
Security
